We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Bradmer’s Phase III Brain Cancer Drug Study
FDA Approves Bradmer’s Phase III Brain Cancer Drug Study
June 6, 2008
Canada’s Bradmer Pharmaceuticals has received a green light from the FDA to start a Phase III clinical trial evaluating a monoclonal antibody that the company says has shown significant survival benefits in previous trials on brain cancer patients.